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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.06.009OBJECTIVE/BACKGROUND: Nucleophosmin 1 (NPM1) plays multiple roles in cell growth and proliferation.
Deletion/insertion mutations in exon 12 of NPM1 (NPM1-DIM), commonly found in patients with acute mye-
loid leukemia (AML), alter the C-terminal amino acids and disrupt the normal nucleocytoplasmic shuttling func-
tion of the protein, which in turn leads to disease pathogenesis. However, this altered function as a result of
NPM1-DIM positivity is actually associated with a significantly better response to therapy and overall survival,
and thus it is of clinical relevance to investigate the mutation status at diagnosis. Our objective was to design a
reliable flow cytometry assay to detect mutated NPM1 in peripheral blood (PB) samples from AML patients,
using a polyclonal mutation-specific antibody.
METHODS: A commercially available NPM1 mutation-specific polyclonal antibody in combination with
a secondary goat antirabbit antibody was used to detect the C-terminal-mutated NPM1 by flow cytometry.
OCI/AML3 (+) cell line and clinical PB controls were used to optimize the assay and determine
sensitivity, reliability, and reproducibility parameters. The assay was then tested on a small cohort of 12 AML
patients at diagnosis and compared with NPM1-DIM testing on a standard polymerase chain reaction (PCR)
platform.
RESULTS: Flow cytometry using the polyclonal antibody was able to reliably detect mutated NPM1 popula-
tions of at least 10%. Using an objective analysis of the mean fluorescent intensity, clear positive and negative
mutated cell populations could be distinguished using the clinical AML samples. From the analysis of 12
patients, 2 were found to be positive using this assay, which corresponded with conventional PCR method-
ology.
CONCLUSIONS: Flow cytometry may be used to detect NPM1 C-terminal mutations in AML patients using a
polyclonal anti-NPM1 antibody, allowing rapid mutation status determination at diagnosis.
KEYWORDS: Acute myeloid leukemia; Flow cytometry; Nucleophosmin 1Acute myeloid leukemia (AML) is character-ized by the rapid proliferation and accumula-tion of immature myeloid precursor cells in
the bone marrow, resulting in disruption of normal
blood cell production.1 AML actually encompasses a
heterogeneous group of diseases that traditionally
relied on morphology, cytochemistry, and cytogeneticanalysis for classiﬁcation into various subtypes and in
turn into different prognostic categories.1,2 In those
AML subtypes with recurrent cytogenetic abnormali-
ties, patients classiﬁed under the ‘‘poor prognostic’’
category would be considered for an allogeneic stem
cell transplant, whereas the others may not.3 Up to
50% of AML patients, however, demonstrate aarter 2015
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normal cytogenetic proﬁle with conventional cytoge-
netics,4 making it difﬁcult to assign these patients to
any prognostic category. In 2008, the World Health
Organization (WHO) introduced a new category
called ‘‘AML with gene mutations,’’ which allows clas-
siﬁcation of AML into prognostic subgroups
depending on the speciﬁc gene mutations or combina-
tions of mutations.1 Mutations in this category
include mutations in Fms-like tyrosine kinase 3
(FLT3), nucleophosmin 1 (NPM1), and chloram-
phenicol acetyltransferase-box enhancer-binding
protein alpha (CEBPA), which carry a high prognos-
tic value.5 In general, NPM1 deletion/insertion muta-
tions (NPM1-DIM)6 and CEBPA point mutations7
are considered to convey a good prognosis; by con-
trast, FLT3 internal tandem duplications (FLT3-
ITD) are considered to convey a poor prognosis.8
The combination of mutations also alters the prog-
nostic value of the individual mutations, with coexis-
tence of FLT3-ITD negating the positive prognostic
effect of NPM1-DIM.9 It is thus of great importance
to be able to rapidly identify these mutations before
initiating treatment protocols.
In cytogenetically normal AML, the most common
NPM1 mutations involve deletions or insertions in
exon 12 (NPM1-DIM), with six major variants being
described (A–F), although the most common muta-
tions involve the insertion of 4 bp.10 Despite varia-
tions in the exact positioning of the mutations, all
resulting mutant NPM1 translation products contain
the same ﬁve C-terminal amino acids. This results in
changes in their nuclear localization signal11 and a
shift in the balance of nuclear export, leading to the
accumulation of NPM1 in the cytoplasm.10,12,13
This nucleocytoplasmic shuttling protein plays an
important role in regulation of ribosomal biogenesis,
as well as cell-cycle regulation during oncogenic
stress,12,14,15 centrosome duplication, and regulation
of apoptosis.16 Its ability to shuttle between the nucle-
olus, nucleus, and cytoplasm is paramount to these
functions, which are severely inhibited by the
NPM1 mutations, thus affecting the growth of the
mutated cells. This actually offers a good prognosis
in AML clones, as tumor growth is negatively
affected.10
Although NPM1-DIM are routinely detected by
polymerase chain reaction (PCR) techniques, an anti-
body that can detect the resulting mutated NPM1
protein could potentially be used in combination with
ﬂow cytometry to provide a relatively quick, simple,
and cost-effective method for detecting these muta-
tions in newly diagnosed AML patients. It could also
be potentially included in the immunophenotypingHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015diagnostic panel with minimal additional effort.
Oelschlaegel et al.17 developed a ﬂow cytometric
method to detect the cytoplasmic localization of
NPM1. However, the monoclonal antibody used in
their study was capable of detecting both mutated
and nonmutated forms, potentially leading to false
positivity or reduced sensitivity. Monoclonal antibod-
ies, raised and selected speciﬁcally to detect the
mutant protein, have been developed by 2 indepen-
dent groups18,19; however, inconsistent results were
obtained and these antibodies are not available com-
mercially. One polyclonal antibody to detect mutated
NPM1 protein is commercially available and has pre-
viously been validated for use in Western hybridiza-
tion assays, but has not been extensively studied in
the application of ﬂow cytometry. The aim of this
study was to develop a ﬂow cytometric method to
detect mutated NPM1 protein in AML patients using
this polyclonal antibody.METHODS AND MATERIALS
Cell lines and clinical samples
The OCI/AML3 cell line, which harbors a con-
ﬁrmed Type A exon 12 NPM1 mutation,20 was
used as a positive control in the development of
the ﬂow cytometry assay (kindly donated by Dr.
P. Szankasi, University of Utah, Salt Lake City,
UT, USA). Cells were cultured in suspension using
a-minimum essential medium/20% fetal bovine
serum (FBS; Gibco, USA). A Jurkat
T-lymphoblastic cell line (ATCC TIB-152) with
wild-type (WT) NPM1 genetics was used as a neg-
ative control for the antibody titration experiments
and was cultured using RPMI-1640/10% FBS
(Gibco, USA). Both cell lines were grown under
standard conditions (37 C, 5% CO2, and 80–90%
humidity).
For the analysis of clinical samples, 5 mL periph-
eral blood (PB) samples were collected into EDTA-
coated tubes over a 6-month period from all newly
diagnosed AML patients (excluding those with acute
promyelocytic leukemia), who were referred to the
National Health Laboratory Services at Groote
Schuur Hospital, Cape Town, South Africa, for ﬂow
cytometric analysis. This produced 12 individual
patients, with no speciﬁc AML subtype selected,
and included those who had both normal and abnor-
mal cytogenetic proﬁles (Table 1). As clinical NPM1
WT controls, 5 mL PB was randomly obtained from
routine patients with normal full blood count results
and PCR-negative NPM1-DIM results. Informed
consent was obtained from each of the participants107
Table 1. AML patient characteristics.
Identifier Age (y) and sex WBC · 109/l % Blasts Leukemia immunophenotypinga WHO classification1 Cytogeneticsb FLT3-ITDc
AML1 46 and M 192 56 117/13/33 AML with maturation Normal Negative
AML2 54 and F 7 32 34/117/13/33 AML without maturation Dup(1)q23q42 Negative
AML3 21 and F 93 93 34/117/11c/33 AML without maturation Normal Negative
AML4 64 and F 186 95 117/13/33 AML without maturation No growth Positive
AML5 23 and F NA 80 117/3/11c/11b/13/14/33/36 AML Normal Positive
AML6 18 and F 165 95 117/13/33 AML without maturation Normal Positive
AML7 58 and F 2 20 34/117/13/33 AML with maturation Normal Negative
AML8 18 and M 144 75 34/117/11c/13/33/64 AML without maturation Normal Negative
AML9 18 and F 9 42 34/117/13/33 AML t(3;3) t(3;3)+ Negative
AML10 69 and M 62 77 34/117/13/33 AML No growth Negative
AML11 35 and F NA >70 117/33 AML without maturation Normal Negative
AML12 45 and F 34 41 117/7/13/33 AML with MDS-related changes Normal Negative
Note: AML = acute myeloid leukemia; MDS = myelodysplastic syndrome; NA = Not available due to referral specimen being analyzed; PB = peripheral blood; WBC = white blood cell; WHO = World Health Organization.
aAll new AML patients PB blast populations were analyzed with the following leukemia flow cytometry panel: CD2, 4, 7, 10, 19, 13, 14, 33, 34, 35, 45, 56. >20% positivity was regarded as positive.bStandard karyotype only reported.
cFLT3-ITD mutation status was determined by National Health Laboratory Service Molecular Haematology-accredited diagnostic laboratory.
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To determine the assay sensitivity, OCI/AML3
cells were serially diluted into PB from the WT con-
trol patients (both sample types standardized to a
ﬁnal white cell count of 10 · 109/L). Dilutions ranged
from 100% to 1% of OCI/AML3-positive cells. These
samples were then analyzed by ﬂow cytometry. The
10% dilution was individually prepared 14 times
(dilution and antibody labeling) and analyzed on 2
separate occasions to assess reproducibility.
Overview of ﬁnal ﬂow cytometry assay
All samples were diluted in phosphate-buffered saline
(PBS) to a standard nucleated cell count of
10 · 109/L. Cell surface staining was performed on
100 lL of the prepared sample using 10 lL of anti-
CD45 peridinin–chlorophyll–protein complex
(Becton Dickinson, USA). After incubating the cells
with anti-CD45 for 15 min, erythrocytes were lysed
using 1 mL FACS Lyse (Becton Dickinson, USA)
for 10 min at room temperature (RT). Samples were
then washed once using 2 mL of 0.5% bovine serum
albumin (BSA) in PBS and the cell pellets were col-
lected by centrifugation at 400g for 5 min. Cell per-
meabilization with FACS perm II (0.5 mL; Becton
Dickinson, USA) was performed for 10 min at 4 C
and the cells were washed one more time with 0.5%BSA/PBS. The cell pellets were collected as described
earlier. Optimal blocking of nonspeciﬁc binding sites
was performed by resuspending the cell pellets in
1 mL of 3:2 ratio of human AB serum to 0.5%
BSA/PBS and incubating at 37 C for 2 h. The sam-
ple was then incubated with 2 lL of NPM1
mutation-speciﬁc polyclonal rabbit antihuman pri-
mary antibody (0.3 mg/mL stock; Abcam, UK) for
30 min at RT. It was then washed two times with
0.5% BSA/PBS and resuspended in 100 lL of the
3:2 AB serum/BSA mixture. Staining with 2 lL
stock solution of secondary goat antirabbit antibody
(Alexa Fluor 488 conjugate, Invitrogen, USA;
0.2 mg/mL) was performed for another 30 min at
RT. Following this secondary antibody labeling step,
the samples were ﬁnally washed two times with
2 mL of 0.5% BSA/PBS and the cell pellets were
resuspended in 1 mL PBS.
Labeled samples were analyzed on an FACS Canto
II instrument (Becton Dickinson, USA), and analyzed
with Kaluza software (Beckman-Coulter). Blast popu-
lations were difﬁcult to isolate in most AML cases
based on CD45 and side-scatter characteristics
alone,21 and CD34 gating was not performed due to
the limited CD34 positivity in some AML cases
(Table 1).17 Instead, the CD45-positive population,
excluding the lymphocyte population, was analyzed,
with a minimum of 10,000 events being acquired inHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
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this gate. For the analysis of all clinical samples, a pos-
itive control (OCI/AML3) and negative control sam-
ple (both obtained on the same day) were
simultaneously analyzed with the AML patient sam-
ples. NPM1 positivity was determined by analyzing
the Alexa Fluor 488 ﬂuorescence of the gated popula-
tion in a histogram format. The median ﬂuorescence
intensity (MFI) of the NPM1 peak for the AML
patients was determined and divided by the MFI of
the NPM1 peak for the simultaneously labeled WT
control sample to generate the normalized NPM1
MFI value. A normalized NPM1 MFI value of 2.0
and above was determined to correspond with
NPM1-DIM PCR positivity.
PCR analysis of NPM1 exon 12 mutation status
The PCR detection of NPM1-DIM was performed in
the Molecular Haematology Diagnostic Unit of the
National Health Laboratory Services at Groote
Schuur Hospital using a validated and South
African National Accreditation System-accredited
methodology. In brief, primers developed by
Laughlin et al.22 were used to amplify the relevant
area of exon 12 of NPM1/NPM1F:
TTTTCCAGGCTATTCAAGATC and NPM1R:
GGACAGCCAGATATCA ACTG [21]. PCR
products were analyzed by capillary electrophoresis
(ABI 3100 genetic analyzer, Applied Biosystems,
USA). GeneMapper 4.1 (Life Technologies, USA)
was used to size the peaks, with a minimum peak
height deﬁned as 50 relative ﬂuorescence units. This
assay was found to be reliable to detect up to 5% of
mutated alleles in our laboratory setting.RESULTS
Assay development
The following 2 key factors were investigated to opti-
mize the differentiation of positive and negative
mutated NPM1 populations (NPMI-DIM associ-
ated): (a) primary/secondary antibody ratio, with
2 lL primary antimutated NPM1 antibody (ﬁnal
concentration 6 lg/mL) and 2 lL secondary antibody
(ﬁnal concentration 7 lg/mL) in a ﬁnal labeling vol-
ume of 104 lL, resulting in the best population dis-
crimination; (b) Reduction of nonspeciﬁc antibody
binding, which is common in dual-labeling scenarios.
Although plastic adherence was attempted to reduce
the monocyte population, and various concentrations
of BSA were used to block the Fc receptors on both
monocyte and neutrophil populations,23 optimal
blocking of Fc receptor sites and thus nonspeciﬁc pos-
itivity was only achieved using a combination ofHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015human AB Rh-negative serum and BSA 0.5%/PBS
(3:2 ratio) for 2 h at 37 C. Figure 1 shows the reduc-
tion in nonspeciﬁc antibody binding using this
approach, whereas the optimal separation of the
anti-NPM1-labeled populations can be seen in
Figure 2A.
Assay sensitivity and reproducibility
Using the optimized parameters, the assay sensitivity
was assessed by diluting the positive control cell line
(OCI/AML3) into PB of WT clinical controls, to
provide a more realistic cellular proﬁle, as opposed
to a negative control cell line only. The following dilu-
tions were assayed in duplicate: 50%, 20%, 10%, and
5%. Gating was performed on the entire CD45-
positive population, as OCI/AML3 cells were not
easily distinguishable from granulocytes, monocytes,
and lymphocytes in these mixed samples. Figure 2
shows the results from the analysis of the 20%,
10%, and 5% mixes. The population of NPM1-
DIM positive cells could be clearly identiﬁed at the
50%, 20%, and 10% level on the relevant histogram;
however, it became progressively more difﬁcult to dif-
ferentiate the NPM1-DIM-positive cells from the
negative population at lower levels (as is seen in
Figure 1C, 5% positive cells). Reproducibility was
evaluated at this 10% sensitivity limit, with 14 individ-
ually prepared 10% mixtures labeled and analyzed on
two separate occasions. All 10% OCI/AML3 cell
mixtures showed clear discrimination between the
two peaks, with the positive NPM1-DIM population
showing a mean MFI of 37.9 compared with the WT
peak of 6.7. The MFI of the mutated NPM1 peak
showed minimal variation with interexperimental
and intraexperimental variability calculated at 6.1%
and 5%, respectively, for the 28 samples analyzed.
Clinical assessment
To determine the speciﬁcity and performance of the
assay in a clinical setting, PB samples from 12 newly
diagnosed AML patients were assayed for NPM1-
DIM using both the proposed ﬂow cytometry
approach (C-terminal-mutated NPM1 detection)
and a routine PCR assay.
The PCR assay indicated that only 2/12 patients
were positive for the exon 12 mutation (type not
deﬁned; Table 2, normal cytogenetic proﬁles). For
the ﬂow cytometric analysis, patient samples were
analyzed on separate days and were coanalyzed with
a 100% positive control OCI/AML3 sample and a
clinically negative PB control sample, to control for
variation in antibody labeling efﬁciencies and instru-
ment ﬂuctuations. Because of the high percentage of109
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Figure 1. Reduction in nonspecific binding. WT PB was labeled with primary anti-NPM1-DIM/secondary Alexa-488 goat antirabbit antibodies and analyzed by flow
cytometry. The CD45-positive population was gated (left panel) and then the false NPM1-DIM positivity was assessed with a histogram of Alexa-488 positivity versus count
(right panel). (A) Generation of a single fluorescent ``false-positive'' peak in the absence of any Fc blocking. (B) Effect of 0.5% BSA blocking prior to antibody labeling, with
the false positivity still evident. (C) Combining human AB Rh-negative serum with 0.5% BSA (3:2 ratio) removes the false positivity by effectively blocking the Fc receptors. It
must be noted that the negative peak was adjusted to a median fluorescence intensity of 5–10 for all subsequent analysis.
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CD45 gating strategy produced a single peak for all
AML patients (examples shown in Figure 3). While
the MFI values of the PCR-positive patients were sig-
niﬁcantly different from the PCR-negative AML cases
(p < .005), unexpectedly these values were alsosigniﬁcantly different from the positive control
OCI/AML3 (i.e., 23.1 AML12 vs. 45.1
OCI/AML3) in the same experiment, which made
it difﬁcult to use the positive control as a gating mar-
ker for determining NPM1 mutation positivity. It is
postulated that this discrepancy may be because theHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
Figure 2. Determination of assay sensitivity. OCI/AML3 cells and wild-type (WT) peripheral blood were mixed in various percentages, blocked with human AB serum/bovine
serum albumin, labeled with primary anti-NPM1-DIM antibody and secondary Alexa-488 goat antirabbit antibody and then analyzed by flow cytometry for NPM1-DIM
detection. The CD45-positive population was gated (left panel) and then the NPM1-DIM population was assessed with a histogram of Alexa-488 positivity versus count (right
panel). Back-gating of the mutated NPM1 population (Gates 1–3, with corresponding color changes) shows the location of a specific CD45-positive population (left panel). (A)
20% OCI/AML3, (B) 10% OCI/AML3 and (C) 5% OCI/AML3 cells.
FLOW CYTOMETRIC METHOD TO DETECT NPM1 original research reportOCI/AML3 cells are much larger than clinically
mutated blasts and have a higher ﬂuorescence due
to the increased content of the mutated protein; how-
ever, this remains to be proven.
In the absence of a ﬁxed gating strategy, to objec-
tively determine NPM1-DIM positivity, we adopted a
similar approach used by Oelschlaegel et al.,17 where
the MFI of each patient’s single peak was normalized
to the WT-negative control peak MFI, to control for
labeling efﬁciency issues between runs. Table 2 presents
the results of this analysis, indicating that the 10
NPM1-DIM PCR-negative (WT) AML patients had
a normalized peak MFI range of 1–1.8 (minimum–
maximum). By contrast, the two NPM1-DIM-Hematol Oncol Stem Cell Ther 8(3) Third Quarter 2015positive patients had normalized MFI values clearly
above 1.8 (AML11, 2.5; and AML12, 2.4). Although
the data set was limited, a receiver operating character-
istic curve analysis indicated that a normalized MFI of
2.0 and above would give the best speciﬁcity and sensi-
tivity to discriminate between NPM1-DIM-positive
and NPM1-DIM-negative AML patients using this
polyclonal antibody speciﬁc for the C-terminal-
mutated NPM1 associated with NPM1-DIM.DISCUSSION AND CONCLUSION
Flow cytometry is gaining importance as an alterna-
tive method to PCR for detection of fusion proteins111
Table 2. NPM1-DIM clinical assessment: AML patient analysis.
Identifier Patient MFIa Positive control Negative control Normalized MFIb NPM1-DIM PCR
MFI MFI
AML1 8.4 27.8 7.7 1.1 Negative
AML2 6.0 29.9 5.1 1.2 Negative
AML3 6.4 29.9 5.1 1.3 Negative
AML4 10.2 48.0 6.1 1.7 Negative
AML5 10.4 48.0 6.1 1.7 Negative
AML6 10.7 48.0 6.1 1.8 Negative
AML7 7.8 33.7 6.9 1.1 Negative
AML8 6.9 33.7 6.9 1.0 Negative
AML9 6.9 33.7 6.9 1.0 Negative
AML10 10.5 34.2 6.3 1.7 Negative
AML11 11.3 19.8 4.7 2.4 Positive
AML12 23.1 45.1 9.4 2.5 Positive
aMFI of single peak generated.
bCalculated as MFI positive peak in sample/MFI peak of clinical negative control.
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study was to develop an alternative method to PCR
for speciﬁcally detecting the mutated NPM1 protein
utilizing ﬂow cytometry and commercially available
reagents.
We developed a ﬂow cytometric assay using the
commercially available Abcam polyclonal antibody to
the mutated NPM1 (associated with NPM1-DIM)
and tested it with relevant cell lines and a small cohort
of clinical AML PB samples. We found that we were
able to correctly identify patients expressing this
mutated protein using a normalized MFI as an objec-
tive indicator of positivity and that the assay had a
10% cellular limit with good reproducibility.
While 2 groups have previously tested monoclonal
antibodies for detecting the mutated C-terminal of
NPM1,18,19 and the studies demonstrated variable
success, with the antibody from Gruszka’s research
group18 showing high speciﬁcity for the mutated
NPM1 protein, whereas Tan et al.19 experienced sig-
niﬁcant cross-reactivity with the WT protein. This
appears to be due to the Fc receptor blocking, which
we optimized for the polyclonal antibody use, but
which was not taken into consideration by Tan et al.19
who only tested the antibody’s performance on an
immunohistochemistry platform, using a peroxidase-
labeled secondary antibody. The Fc receptor blocking
in this complex intracellular secondary-antibodylabeling methodology is therefore essential to ensure
the prevention of false positivity.
Gruszka et al.18 found the sensitivity of their assay
to be as low as 0.001%, whereas that of our assay was
10%. Unlike our study, Gruszka et al.18 only tested
the assay performance using single-population HL60
and OCI/AML3 cell line mixtures, which do not sim-
ulate the normal scenario faced when dealing with
clinical specimens containing different cell types.
They also used a monoclonal antibody, which allows
for a higher speciﬁcity and thus higher sensitivity than
polyclonal antibodies. We feel that our study using
normal PB as the diluent for the OCI/AML3 cells
better represents the sensitivity in the clinical setting.
The use of this polyclonal antibody raised against the
mutated NPM1 also offers better speciﬁcity com-
pared with the method of Oelschlaegel et al.17 which
relies on the localization of the protein and thus the
preservation of cell integrity to prevent false positivity.
While our assay would not be suitable for minimal
residual disease detection after therapy or transplanta-
tion, a sensitivity level of 10% is clinically acceptable
because most diagnostic AML samples will contain
in excess of 20% blasts, all of which should be positive
for the NPM1-DIM.1 No additional personnel or
equipment is required to perform the ﬂow cytometry
in a laboratory where these functions have already
been established and it is possible to incorporate thisHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
Figure 3. Clinical evaluation of AML patients and controls. CD45-positive cells (excluding lymphocytes; left panel) were evaluated for mutated NPM1 using a histogram of
Alexa Fluor 488 fluorescence. The MFI of the observed peak is indicated. (A) 100% OCI/AML3-positive control, (B) WT PB-negative control, (C) NPM1-DIM PCR-positive
patient AML12 and (D) NPM1-DIM PCR-negative patient AML4.
FLOW CYTOMETRIC METHOD TO DETECT NPM1 original research reportassay into an existing leukemia ﬂow panel and obtain
results within 24 h.
The presence of NPM1-DIM in patients with
AML is strongly associated with a normal cytogenetic
karyotype.28 Cytogenetic analysis is a labor-intensive
process with long turnaround times and is costly.29
No cases of AML with an NPM1 mutation have
yet been shown to have the recurrent cytogenetic
abnormalities described in the WHO AML classiﬁca-
tion,28 potentially obviating the need to perform cyto-
genetic testing when this mutation is present. ThisHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015may also be an advantage for laboratories that do
not have the necessary facilities to perform cytogenetic
testing, which then requires transporting samples over
great distances to facilitate these tests. Consequently,
this often results in assay failure due to aging of sam-
ples.29 The cost of this assay was also found to be 10
times cheaper than the standard cytogenetic panel,
offering a potential cost-saving option when per-
formed ﬁrst. The ﬂow cytometric assay described in
this study is therefore of potential use in a resource-
restricted diagnostic environment, especially in113
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nonﬁrst world countries. Further validation with a
larger AML cohort is required, and it may provide a
key mutation detection alternative method.CONFLICTS OF INTEREST
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